Volume | 12,221 |
|
|||||
News | - | ||||||
Day High | 3.79 | Low High |
|||||
Day Low | 3.52 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
SAB Biotherapeutics Inc | SABS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.75 | 3.52 | 3.79 | 3.63 | 3.87 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
155 | 12,221 | $ 3.70 | $ 45,244 | - | 3.52 - 10.50 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:03:29 | 3 | $ 3.46 | USD |
SAB Biotherapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
34.13M | 9.23M | - | 2.24M | -42.19M | -4.57 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
SAB Biotherapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SABS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.85 | 4.23 | 3.52 | 3.99 | 9,168 | -0.22 | -5.71% |
1 Month | 4.265 | 4.65 | 3.52 | 4.04 | 5,720 | -0.635 | -14.89% |
3 Months | 4.88 | 6.30 | 3.52 | 4.81 | 12,015 | -1.25 | -25.61% |
6 Months | 8.80 | 9.721 | 3.52 | 7.14 | 30,071 | -5.17 | -58.75% |
1 Year | 8.51 | 10.50 | 3.52 | 7.85 | 43,674 | -4.88 | -57.34% |
3 Years | 78.00 | 120.90 | 3.52 | 25.82 | 229,883 | -74.37 | -95.35% |
5 Years | 78.00 | 120.90 | 3.52 | 25.82 | 229,883 | -74.37 | -95.35% |
SAB Biotherapeutics Description
SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing fully human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The company's lead asset, SAB-142, targets Type-1 diabetes (T1D) with a disease-modifying therapeutic approach that aims at changing the treatment paradigm by delaying onset and potentially preventing disease progression. |